Bradley J. Bolzon PhD - Jun 28, 2021 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Director
Signature
/s/ Robin L. Praeger, attorney-in-fact for Bradley Bolzon
Stock symbol
CRSP
Transactions as of
Jun 28, 2021
Transactions value $
-$4,631,583
Form type
4
Date filed
6/30/2021, 06:38 PM
Previous filing
Jun 23, 2021
Next filing
Jul 21, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Sale -$484K -3.22K -15.78% $150.65 17.2K Jun 28, 2021 Direct F1, F2
transaction CRSP Common Shares Sale -$238K -1.58K -0.93% $150.65 167K Jun 28, 2021 See Footnote F1, F2, F3, F4
transaction CRSP Common Shares Sale -$970K -6.4K -37.32% $151.49 10.8K Jun 28, 2021 Direct F1, F5
transaction CRSP Common Shares Sale -$476K -3.14K -1.88% $151.49 164K Jun 28, 2021 See Footnote F1, F3, F4, F5
transaction CRSP Common Shares Sale -$478K -3.14K -29.18% $152.38 7.62K Jun 28, 2021 Direct F1, F6
transaction CRSP Common Shares Sale -$235K -1.54K -0.94% $152.38 163K Jun 28, 2021 See Footnote F1, F3, F4, F6
transaction CRSP Common Shares Sale -$694K -4.52K -59.33% $153.54 3.1K Jun 28, 2021 Direct F1, F7
transaction CRSP Common Shares Sale -$341K -2.22K -1.36% $153.54 160K Jun 28, 2021 See Footnote F1, F3, F4, F7
transaction CRSP Common Shares Sale -$353K -2.28K -73.63% $154.57 817 Jun 28, 2021 Direct F1, F8
transaction CRSP Common Shares Sale -$173K -1.12K -0.7% $154.57 159K Jun 28, 2021 See Footnote F1, F3, F4, F8
transaction CRSP Common Shares Sale -$41.6K -268 -32.8% $155.27 549 Jun 28, 2021 Direct F1, F9
transaction CRSP Common Shares Sale -$20.5K -132 -0.08% $155.27 159K Jun 28, 2021 See Footnote F1, F3, F4, F9
transaction CRSP Common Shares Sale -$85.9K -549 -100% $156.54 0 Jun 28, 2021 Direct F1, F10
transaction CRSP Common Shares Sale -$42.1K -269 -0.17% $156.54 159K Jun 28, 2021 See Footnote F1, F3, F4, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.00 to $150.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 These Securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person.
F4 These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
F5 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.00 to $151.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
F6 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $152.00 to $152.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.
F7 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $153.02 to $153.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.
F8 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $154.00 to $154.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4.
F9 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $155.23 to $155.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (9) to this Form 4.
F10 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $156.26 to $156.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (10) to this Form 4.

Remarks:

1/2: Since there are more than 30 rows associated with the applicable transactions and EDGAR will not allow for the entry of more than 30 rows on a single Form 4, this Form 4 is being filed in conjunction with a second Form 4 by the Reporting Person. The two Form 4s filed by the Reporting Person on the date hereof should be read together as one consolidated filing.